Diagnostic Performance of Serum (1,3) β-D Glucan to Detect Fungal Infection in Acute Leukemia Patients with Chemotherapy
Abstract
Chemotherapy is a predisposing factor for infection in patients with malignancy, while culture, as the gold standard,
limits the diagnosis of fungal infections. (1,3) β-D glucans, the most abundant polysaccharide component of the fungal wall,
are increased in patients with Invasive Fungal Infections (IFI). This research was an analytical observational study with a
cross-sectional approach involving 60 acute leukemia patients who received chemotherapy with suspicion of fungal
infection at the General Hospital of Dr. Moewardi, Surakarta, from September to October 2019. Fungal blood cultures and
serum (1,3) β-D glucan levels by the enzyme-linked immunoassay method were examined. Diagnostic tests were performed
to determine sensitivity, specificity, Positive Predict Value (PPV), Negative Predict Value (NPV), Positive Likehood Ratio (PLR),
Negative Likehood Ratio (NLR), and the serum's accuracy value (1,3) β-D glucan levels to fungal culture. Most (88.3%) of
patients were diagnosed with Acute Lymphocytic Leukemia (ALL), maintenance chemotherapy phase (51.3%), risk factors
for neutropenia (50%), and intravenous (IV) line use (56.7%). Serum (1,3) β-D glucan levels in patients with positive fungal
cultures (4) in blood samples had a median of 482.87 (476.13-640.56) pg/mL, while patients with negative fungal cultures
(56) had a mean±SD 298,68±114,39 pg/mL. Diagnostic test with a cut-off of 471,717 pg/mL showed sensitivity of 100.0%,
specificity of 96.4%, NPV of 100%, PLR of 28.00, and NLR of 0.00 with an Area Under Curve (AUC) value of 0.982 and
Coefficient Interval (CI) 95% (0.950-1.014). The measurement of serum (1,3) β-D glucan at a cut-off value of 471,717 pg/mL
showed good performance as a biomarker for diagnosing and screening IFIs.
Keywords
Full Text:
PDFReferences
Bartlett AW, Cann MP, Yeoh DK, Bernard A, Ryan AL,
et al. Epidemiology of invasive fungal infections in
immunocompromised children; An Australian
national 10-year review. Pediatric Blood & Cancer,
; 66(4): e27564.
Patricia T. Pola jamur dan resistensi antijamur pada
pasien dengan penyakit keganasan di RSUD Dr.
Moewardi Surakarta periode Januari-Desember 2019.
Karya stase Mikrobiologi. Program Pendidikan
Spesialis Patologi Klinik, Fakultas Kedokteran
Universitas Sebelas Maret Surakarta. 2019.
Crawford J, Dale DC, Lyman GH. Chemotherapy-induced
neutropenia: Risks, consequences, and new directions
for its management. Cancer, 2004; 100(2): 228-237.
Latgé JP. The cell wall: A carbohydrate armor for the
fungal cell. Mol Microbiol, 2007; 66(2): 279-290.
Wright WF, Overman SB, Ribes JA. (1–3) β-D-glucan
assay: A review of its laboratory and clinical application.
Laboratory Medicine, 2011; 42(11): 679–85.
Iossifova Y, Reponen T, Daines M, Levin L, Hershey
GKK. Comparison of two analytical methods for
detecting (1,3) β-D glucan in pure fungal cultures and
in-home dust sample. The Open Allergy Journal, 2018;
: 26-34.
Anonim. Lipopolysaccharides (LPS) ELISA kit may
substitute for Limulus Amebocyte Lysate (LAL) test
reagen. Cloud-clone corp; Http www-cloud
clone.com/topic/201305071641290001.html. 2013.
(accessed 14 October, 2019).
Pagano L, Mayor S. Invasive fungal infections in
high-risk patients: Report from TIMM-8 2017. Future
Science OA, 2018; 4(6): 1-10.
Cancer Research UK. Acute lymphoblastic leukemia
phase treatment, diunduh dari https://www.
c a n c e r r e s e a r c h u k . o r g / a b o u t - c a n c e r /
a c u t e - l y m p h o b l a s t i c - l e u k a e m i a - a l l /
treatment/phases. 2018. (accessed 14 October, 2019).
Lien MY, Chou CH, Lin CC, Bai LY, Chiu CF, et al.
Epidemiology and risk factors for invasive fungal
infections during induction chemotherapy for newly
diagnosed acute myeloid leukemia: A retrospective
cohort study. PLos One, 2018; 13(6): e0197851.
Brigitte L, Pascal R, Gérard C, Jean-Pierre F, Marie L.
What is the relevance of obtaining multiple blood
samples for culture? A comprehensive model to
optimize the strategy for diagnosing bacteremia.
Clinical Infectious Diseases, 2002; 35(7): 842–850.
Azoulay E, Guigue N, Darmon M, Mokart D, Lemiale V,
et al. (1, 3)-β-D-glucan assay for diagnosing invasive
fungal infections in critically ill patients with
hematological malignancies. Oncotarget, 2016; 7(16):
–21495.
DOI: http://dx.doi.org/10.24293/ijcpml.v27i1.1598
Refbacks
- There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.